Optimizing Rheumatology Prior Authorizations with Klivira's Rhyme Platform

Klivira's Rhyme platform brings targeted automation to the complex world of rheumatology prior authorizations, addressing the unique challenges of biologic and advanced therapy approvals.

Revenue cycle directors and prior authorization coordinators in rheumatology face a high-volume, high-complexity PA burden, primarily driven by expensive biologics and targeted synthetic DMARDs. Navigating payer-specific step therapy, biosimilar mandates, and stringent documentation requirements diverts valuable clinical time. Klivira's Rhyme solution is engineered to mitigate these operational hurdles.

The Unique Prior Authorization Landscape in Rheumatology

Rheumatology prior authorizations are heavily concentrated in biologic and targeted therapies for chronic conditions like rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and lupus. The high cost and specialized nature of these agents, including TNF-alpha inhibitors (e.g., adalimumab, etanercept), non-TNF biologics, and JAK inhibitors (e.g., tofacitinib, baricitinib), place rheumatology among the highest PA-burden specialties. Klivira's Rhyme platform is designed to handle this complexity at scale.

Key PA Triggers in Rheumatology Workflows

Biologics: TNF-alpha inhibitors (Humira, Enbrel, Remicade, Cimzia, Simponi, and biosimilars)
Non-TNF biologics and targeted synthetic DMARDs: IL-6, IL-17, IL-23 inhibitors, B-cell depletion, JAK inhibitors (Xeljanz, Olumiant, Rinvoq)
Specialty drugs for specific indications: anifrolumab, belimumab, tildrakizumab, ustekinumab
Advanced imaging: MRI for inflammatory arthritis assessment, ultrasound-guided joint injections
DEXA scans: for osteoporosis management in chronic-steroid patients

Navigating Intricate Documentation and Payer Policies

Payer requirements for rheumatology PAs frequently align with ACR Treatment Guidelines (src: acr-treatment-guidelines), demanding precise documentation. This includes specific ICD-10 codes with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA), quantitative disease activity assessments (DAS28, CDAI, PASI, BASDAI, SLEDAI), and evidence of prior conventional DMARD trials. Furthermore, step therapy compliance, biosimilar substitution mandates, and completion of pre-initiation screenings (TB, hepatitis B/C, immunizations) are critical for approval, especially for immunosuppressive biologics and JAK inhibitors.

Common Rheumatology PA Denial Reasons Addressed by Klivira

Failure to document specific prior agent trial in the required step therapy sequence
Denial of brand TNF inhibitor when biosimilar substitution is mandated by payer policy
Missing or insufficient disease activity scores (DAS28, CDAI, PASI, etc.)
Insufficient duration of conventional DMARD trial as per payer requirements
Incomplete documentation of pre-treatment screenings (TB, hepatitis, immunizations)
Off-indication use without supporting payer-specific policy or clinical rationale

Klivira's Rhyme Platform for Rheumatology PA Automation

Klivira's Rhyme platform is purpose-built to address the unique workflow constraints of rheumatology. This includes managing chronic-treatment ongoing PA burdens with periodic re-authorization workflows, adapting to non-uniform biosimilar substitution policies across major payers, and navigating complex step therapy rules that interact with brand-vs-biosimilar mandates. Our solution also distinguishes between medical and pharmacy benefit PAs for the same agent based on administration mode, and incorporates logic for pediatric-specific PA flows, including weight-based dosing and pediatric guideline criteria.

Seamless Integration for Rheumatology Workflows

Klivira integrates directly with your existing EMR via SMART on FHIR, ensuring clinical data flows securely and efficiently. We connect to payer portals and leverage X12 278, ePA, NCPDP SCRIPT, and Da Vinci PAS standards to submit prior authorizations through the most efficient channel. This comprehensive approach minimizes manual data entry, automates documentation retrieval, and provides real-time status updates, allowing rheumatology practices to focus on patient care rather than administrative tasks.

Frequently asked questions

How does Klivira's Rhyme platform handle the variable step therapy requirements for biologics in rheumatology?

Klivira's Rhyme platform incorporates ACR-guideline-aware policy logic that dynamically adapts to payer-specific step therapy sequencing. This ensures that the correct prior agent trials are documented and submitted, significantly reducing denials related to non-compliance with payer protocols.

Can Klivira manage re-authorizations for chronic rheumatology treatments like biologics?

Yes, Klivira's Rhyme platform includes a dedicated workflow for periodic re-authorizations common in chronic rheumatology treatments. It tracks re-authorization due dates and prompts for necessary continuous response documentation, ensuring timely submissions and uninterrupted patient access to critical medications.

How does Klivira address biosimilar substitution mandates from different payers?

Our platform features robust biosimilar substitution routing logic that accounts for per-payer mandates. Klivira's Rhyme guides the workflow to ensure that biosimilar trials are documented and submitted when required, or facilitates brand-to-biosimilar conversion workflows as dictated by payer policies.

What EMR systems does Klivira integrate with for rheumatology workflows?

Klivira offers broad integration capabilities with leading EMR systems through industry standards like SMART on FHIR. This allows for seamless data exchange, pulling necessary clinical documentation directly from the patient chart to populate prior authorization requests without manual transcription.

How does Klivira's Rhyme platform differentiate between medical and pharmacy benefit PAs for the same rheumatology drug?

Klivira's Rhyme platform is configured to intelligently route prior authorizations based on the specific benefit (medical vs. pharmacy) and administration mode of the agent. This ensures that the correct PA process is initiated, whether the drug is self-administered or provider-administered, aligning with payer-specific policies.